StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT)

Equities researchers at StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report released on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners began coverage on vTv Therapeutics in a research report on Monday, December 9th. They issued a “buy” rating and a $35.00 price objective for the company.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $14.89 on Tuesday. The stock has a fifty day moving average price of $16.40 and a two-hundred day moving average price of $15.38. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $30.99. The company has a market cap of $47.48 million, a price-to-earnings ratio of -3.29 and a beta of 1.07.

Institutional Investors Weigh In On vTv Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 1,327 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics during the fourth quarter worth $25,000. Finally, FMR LLC bought a new stake in shares of vTv Therapeutics during the third quarter worth $2,402,000. Institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.